Accelerating Drug Development is a Moral Imperative with Dr. Gabi Hanna, MD
Description
For our first episode of season three, I sat down with Gabi Hanna, MD, CEO and co-founder of Lamassu Biotech, where he leads the development of innovative therapies for cancer and inflammatory diseases. A physician-scientist and serial entrepreneur, Dr. Hanna previously founded the first academic drug development center at Duke University and has authored over 50 peer-reviewed publications. Under his leadership, Lamassu is advancing two novel therapeutics—RABI-767, now in Phase II trial, and SA53, a first-in-class oncology compound currently in Phase I/II trial. He also oversees Lamassu Pets, which is developing a canine therapy for pancreatitis. Dr. Hanna’s work is driven by a commitment to rapid, cost-effective drug development that addresses unmet clinical needs.
We discuss the mission of Lamassu Biotech, as well as the importance of academic accelerator programs, overcoming regulatory roadblocks, and the moral duty to accelerate drug development for patient care. Gabi emphasizes the need for efficient operations, strategic partnerships, and a patient-centric approach in biotech. We also explore the potential for policy changes to improve collaboration between universities and biotech companies, as well as the importance of ethical considerations in drug development. Dr. Hanna’s's insights provide valuable guidance for both entrepreneurs and those working in the biotech industry.
- Connect with Dr. Gabi Hanna on LinkedIn
- Follow Lamassu Biotech on LinkedIn
- Learn More about Lamassu Biotech
Connect with us!
Subscribe here:
Learn more about Recruitomics Consulting
Check out our reading list
Download our free startup resources guide to grow your biotech efficiently
If you're on the job market, visit the Collaboratory Career Hub
00:00 Introduction
00:13 Mission and Work at Lamassu Biotech
01:24 Previous Experience at Duke University
03:50 Challenges and Strategies in Biotech
06:48 Accelerating Drug Development
08:24 Navigating Regulatory Hurdles
14:19 The Role of the FDA and Knowledge Sharing
18:01 Maintaining US Biotech Leadership
27:15 Entrepreneurial Insights and Team Building
35:47 Final Thoughts and Contact Information
United States
